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Abstract
Adult female rats continuously exposed to androgens from prepuberty have reproductive and metabolic features of
polycystic ovary syndrome (PCOS). We investigated whether such exposure adversely affects estrous cyclicity and the
expression and distribution of gonadotropin-releasing hormone (GnRH), GnRH receptors, and corticotrophin-releasing
hormone (CRH) in the hypothalamus and whether the effects are mediated by the androgen receptor (AR). We also assessed
the effect of low-frequency electro-acupuncture (EA) on those variables. At 21 days of age, rats were randomly divided into
three groups (control, PCOS, and PCOS EA; n=12/group) and implanted subcutaneously with 90-day continuous-release
pellets containing vehicle or 5a-dihydrostestosterone (DHT). From age 70 days, PCOS EA rats received 2-Hz EA (evoking
muscle twitches) five times/week for 4–5 weeks. Hypothalamic protein expression was measured by immunohistochemistry
and western blot. DHT-treated rats were acyclic, but controls had regular estrous cycles. In PCOS rats, hypothalamic medial
preoptic AR protein expression and the number of AR- and GnRH-immunoreactive cells were increased, but CRH was not
affected; however, GnRH receptor expression was decreased in both the pituitary and hypothalamus. Low-frequency EA
restored estrous cyclicity within 1 week and reduced the elevated hypothalamic GnRH and AR expression levels. EA did not
affect GnRH receptor or CRH expression. Interestingly, nuclear AR co-localized with GnRH in the hypothalamus. Thus, rats
with DHT-induced PCOS have disrupted estrous cyclicity and an increased number of hypothalamic cells expressing GnRH,
most likely mediated by AR activation. Repeated low-frequency EA normalized estrous cyclicity and restored GnRH and AR
protein expression. These results may help explain the beneficial neuroendocrine effects of low-frequency EA in women
with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is characterized by hyper-
androgenism and anovulation. Its origin appears to be multifac-
torial, as increased concentrations of luteinizing hormone (LH)
and insulin stimulate the ovaries and increase androgen secretion
[1]. PCOS is also associated with obesity, hyperinsulinemia, and
insulin resistance, and women with the syndrome are at increased
risk of metabolic disorders, which exacerbate the symptoms of
PCOS [1]. Regardless of the etiology, increased androgen
concentrations appear to result in neuroendocrine dysfunction.
The neuroendocrine characteristics of PCOS are elevations in
the pulse frequency and amplitude of gonadotropin-releasing
hormone (GnRH). The resulting increase in pituitary synthesis of
LH contributes to excessive LH pulsatility and a relative deficiency
in follicle-stimulating hormone (FSH) [2]. High LH concentrations
increase ovarian androgen production, and FSH deficiency
contributes to impaired follicular development [3]. In adult female
rats prenatally exposed to androgen, androgen receptor (AR)
activation appears to contribute directly to the development of a
hyperactive GnRH pulse generator [4]. Corticotropin-releasing
hormone (CRH) may also modulate GnRH release [5] and thus
may be involved in the neuroendocrine dysfunction. We
developed a rat model of PCOS that recapitulates the ovarian
and metabolic characteristics of PCOS. After continuous exposure
to the nonaromatizable androgen dihydrotestosterone (DHT) from
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6638prepuberty, adult rats have polycystic ovaries, an increased
number of apoptotic follicles, and irregular cycles [6].
Many women with PCOS require prolonged pharmacological
treatments, which are usually effective but have adverse effects [7].
Therefore, new nonpharmacological treatment strategies such as
acupuncture need to be evaluated [8]. In women with PCOS and
women with undefined ovulatory dysfunction, repeated low-
frequency electro-acupuncture (EA) has long-lasting beneficial
effects on endocrine parameters and ovulation with no negative
side effects [9,10]. In our rat model of DHT-induced PCOS and in
a rat model of PCO induced by estradiol valerate, we
demonstrated that low-frequency EA modulates ovarian morphol-
ogy [11,12], improves insulin sensitivity [11], and inhibits
hyperactivity in the sympathetic nervous system [12–16]. Howev-
er, the mechanism of those effects, and the effects of acupuncture
on neuroendocrine dysfunction, were not investigated.
Our hypothesis is that low-frequency electro-acupuncture (EA)
with needle placement in abdominal and leg muscle (i.e., somatic
innervation that corresponds to the ovaries) activatesA-delta and C-
fibers to restore endocrine, neuroendocrine, metabolic, and
autonomic function [12–16]. We used low-frequency EA (rather
than needle penetration without electrical stimulation) because it
improved irregular menstruation and decreased circulating testos-
terone in women with PCOS in uncontrolled studies [9,10].
Further, in basic experimental studies in which we systematically
tested different stimulation frequencies and intensities and needle
placements, the optimal ovarian response was obtained with low-
frequency EA (2 Hz with 0.1-sec, 80-Hz burst pulses) at a
stimulation intensity high enough to evoke muscle twitches and
with needle placement in abdominal and hind limb muscles [12–
16]. We also showed that the effectof low-frequency EA is mediated
by sympathetic nerves via the central nervous system [12–16].
In the present study, we sought to determine whether androgen
exposure, starting before puberty, affects estrous cyclicity and
hypothalamic expression of the AR, GnRH, GnRH-R, and CRH
in adult female rats and whether the effects are mediated by the
AR. We also aimed to test the hypothesis that low-frequency EA,
with intensity high enough to evoke muscle twitches, restores
estrous cyclicity and hypothalamic protein expression in rats with
DHT-induced PCOS. Our findings may help explain the
beneficial neuroendocrine effects of low-frequency EA in women
with PCOS.
Results
Improvement in estrous cyclicity
Control rats had 4–5-day estrous cycles, comprising diestrus,
proestrus, estrus, and metestrus (Fig. 1A). Rats with DHT-induced
PCOS had no dynamic change in estrous cycle, were constantly in
diestrus, and exhibited predominantly leukocytes. During the first
week of treatment, some rats in the PCOS EA group started to
exhibit epithelial keratinocytes, the main cell type during estrus,
indicating estrous cycle changes. After 4–5 weeks of low-frequency
EA treatment, 11 of 12 rats (91.7%) in the PCOS EA group
exhibited epithelial keratinocytes (Fig. 1A, 1B).
Decreased AR protein expression in the hypothalamus
Hypothalamic AR protein expression was higher in PCOS rats
than in controls (p,0.001) (Fig. 2), and so was AR immunoreac-
tivity (AR-ir) in the medial preoptic area (MPO) (p,0.05) (Fig. 3A,
3B). Low-frequency EA decreased hypothalamic AR protein
expression (p,0.05, Fig. 2) and AR-ir in the MPO and the
ventromedial hypothalamus (VMH) to lower levels than in the
PCOS group (Fig. 3A, 3B).
Functional androgen response elements are present in the
promoter sequences of p21 [17], and the regulation of p21
expression is AR dependent [18]. To determine whether the AR
was functionally active, we analyzed hypothalamic samples for AR
activation in response to expression of p21, which regulates cell-
cycle progression and correlates inversely with the levels of active
AR. In both PCOS groups, p21 levels were lower than in controls
by western blot analysis (Fig. 2). Western analysis revealed similar
decreases in the expression of c-FOS, an early marker of neuronal
activation [19], in the PCOS groups (Fig. 2). However, low-
frequency EA did not elicit additional effects on p21 or c-FOS
expression in PCOS rat hypothalamus.
Reduced number of highly GnRH-immunoreactive
hypothalamic cells
GnRH-immunoreactive (GnRH-ir) cells are abundant in the
MPO, rostral medial septum (MS), and nucleus of the horizontal
limb of the diagonal band (HDB) of the hypothalamus [20]. PCOS
rats had more GnRH-ir cells in the MPO and HDB than control
rats (p,0.05) (Fig. 4A, 4B). After 4–5 weeks of EA treatment,
PCOS EA rats had fewer GnRH-ir cells in those areas (p,0.05)
(Fig. 4A, 4B) than the PCOS group. However, there was no
obvious difference in the MS between the control, PCOS, and
PCOS EA groups (Fig. 4A, 4B). Even though we detected GnRH-
ir cells in hypothalamus, we failed to detect a GnRH band by
western blot analysis, because of low GnRH expression. The low
expression was confirmed by immunoprecipitation and western
blot (Fig. 4C).
No effect on hypothalamic GnRH-R expression
The GnRH-receptor (R) is mainly distributed in the pituitary
gland and hypothalamus in the central nervous system. Contin-
uous DHT exposure decreased both the number of GnRH-R-ir
cells in the pituitary, MPO, and HDB (p,0.01) and hypothalamic
GnRH-R protein expression (p,0.05 vs. controls) (Fig. 5A, 5B,
5C). There was no difference in the MS between groups (Fig. 5C).
Low-frequency EA treatments did not affect the number of
GnRH-R-ir cells or the level of GnRH-R expression.
No effect on hypothalamic CRH expression
Two main regions in the hypothalamus, the paraventricular
nucleus (PVN) and MPO, showed CRH-immunoreactivity (CRH-
ir). However, CRH-ir and CRH protein expression did not differ
between PCOS and control rats or after 4–5 weeks of EA
treatment (Fig. 6A, 6B, 6C).
Expression of AR in GnRH-ir or CRH-ir neurons in the
MPO
Dual-fluorescence immunohistochemistry and confocal analysis
showed co-localization of AR, GnRH, and CRH with the
neuronal marker NeuN in controls. In addition, AR and GnRH
expression in the MPO co-localized in the cytoplasm and nucleus,
but few cytoplasmic ARs co-localized with CRH-expressing
neurons (Fig. 7A–G).
Discussion
The molecular mechanisms of AR activation in the develop-
ment of a hyperactive GnRH pulse generator are not well defined.
This study shows that continuous DHT exposure, starting before
puberty, inhibits normal estrous cyclicity and increases hypotha-
lamic AR expression and the number of GnRH-ir cells in adult
female rats. We found direct evidence that the AR co-localizes
Neuroendocrine Effects of EA
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6638Figure 1. Vaginal smears and estrous cycle patterns of control, PCOS, and PCOS EA rats. A) Representative vaginal smears from a normal
cycling control rat at different stages in the estrous cyclediestrus (top left), proestrus (top right), estrus (middle left), and metestrus (middle right).
Representative hematoxylin eosin stained vaginal smear from a PCOS rat exhibiting predominantly leukocytes, the main cell type during diestrus
stage (bottom left). Representative vaginal smear from a PCOS EA rat exhibiting epithelial kerotinocytes, the main cell type during estrus stage
(bottom right). Scale bar, 100 mm (top left). B) Estrous cycle patterns at 70–95 days of age (i.e., 49–84 days after pellet implantation) in four
representative rats from each group. P, proestrus; E, estrus; M, metestrus; and D, diestrus.
doi:10.1371/journal.pone.0006638.g001
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for 4–5 weeks, improved estrous cyclicity and reduced AR and
GnRH protein expression.
Exogenous androgen exposure undoubtedly results in andro-
genic actions at all level of the female reproductive axis [21].
Clinical and animal studies suggest that PCOS has a develop-
mental origin, in which androgen excess during fetal or
prepubertal life reprograms multiple tissues to manifest the
syndrome in adolescence and adulthood [22,23]. Interestingly,
female rats that received DHT continuously, starting before
puberty, had arrested cycles. Previously, we showed that these rats
develop ovarian characteristics of PCOS in adulthood [6].
Further, AR protein expression was increased in the hypothala-
mus, primarily in the MPO, in DHT-treated rats. This effect is
most likely due to AR activation. We also showed that the
circulating estradiol concentration is unchanged in DHT-treated
rats [6]. Thus, there is no cross talk in MPO between AR and ER
in DHT-treated rats.
The effect of excessive androgens on the activity of the GnRH
pulse generator has been explained in part [21,24]. However, it is
unclear whether androgens exert physiological or pathophysiolog-
ical actions in females by activating AR expression in GnRH-
expressing neurons [21]. In the brain, GnRH is the primary
upstream regulator of reproductive function, including estrous
cyclicity in females. Intrinsic and extrinsic stimulation, such as
circulating estrogen and androgen, physical exercise, or stress, can
activate GnRH signaling to regulate the hypothalamic-pituitary-
gonadal axis [25]. But rodent brain has few GnRH neurons, about
600–2000 cells [20,26], and the highest density of the cells is in the
MS, diagonal band of Broca, and MPO [27]. Under most
conditions, it is hard to detect the GnRH protein because of the
limited sensitivity of general western blotting methods. Therefore,
immunohistochemistry and PCR are the most commonly used
methods to study GnRH synthesis and expression.
The effect of excessive androgens on the activity of the GnRH
pulse generator has been analyzed [24]. However, it has been
unclear whether androgens exert physiological or pathophysiolog-
ical actions in females by activating AR expression in GnRH-
expressing neurons [21]. Given the failure of initial efforts to detect
ARs or estrogen receptors in GnRH-expressing neurons
[28,29,30], many investigators concluded that steroid hormones
affect GnRH indirectly [31,32]. Later, coexpression of GnRH and
estrogen receptor b was demonstrated, indicating a direct action of
sex steroids in regulating GnRH [33]. Nevertheless, evidence that
the AR has a role in regulating the function of GnRH-expressing
neurons in vivo has not been presented. Our findings demonstrate
that DHT exposure increases both GnRH and AR expression in
the MPO. The distribution of AR and GnRH overlapped,
indicating a potential mechanism for the regulation of GnRH-
expressing neurons by androgens. This possibility was further
confirmed by the co-localization of AR and GnRH in the MPO,
including both cytoplasmic and nuclear expression.
Over 50% of women with PCOS have excess levels of adrenal
androgens [34], but it is not known whether this excess reflects
hypothalamus-pituitary-adrenal axis dysfunction due to exagger-
ated pituitary secretion of ACTH in response to hypothalamic
CRH, excess responsiveness of adrenal androgens to ACTH
stimulation, or both [33,34]. Adrenal androgen excess in women
with PCOS may not be related to an altered pituitary response to
CRH or to increased sensitivity to ACTH [33]. Rather, increased
secretion of adrenal androgen may be due to increased zonae
reticularis mass or to P450c17 alpha activity. This possibility needs
to be assessed. Consistent with these observations in humans,
hypothalamic CRH protein expression was not affected in rats
with DHT-induced PCOS. Therefore, the decreased circulating
corticosterone concentrations in these rats in our previous study
[11] is most likely due to a local effect in the adrenal gland.
Intramuscularinsertionofacupunctureneedlescausesaparticular
pattern of afferent activity in peripheral nerves [35]. Needle
placement in muscles with the same somatic innervation as the
ovaries modulates ovarian blood flow via ovarian sympathetic
nerves, and the response is controlled by supraspinal reflexes [36–
38]. Further, low-frequency EA modulates the release of endorphins
[39,40], and the central b-endorphin system exerts regulatory
control on the GnRH pulse generator and on pituitary LH release
and modulates sympathetic tone [41]. Evidence that b-endorphin
participates in the regulation of GnRH/LH secretion in PCOS
comes from a recent trial in women with PCOS, in which
naltrexone, a mu-receptor antagonist, induced ovulation and
decreased LH levels, the LH/FSHratio, and testosterone levels[42].
Repeated low-frequency EA restored the estrous cycle, starting
from the first week of treatment, and reduced the increases in
hypothalamic AR and GnRH expression inrats with DHT-induced
PCOS. The mechanism may involve direct or indirect regulation of
AR- and GnRH-expressing neurons in the MPO, as evidenced by
the co-localization of AR and GnRH in neurons. Whether b-
endorphin is involved in this regulation remains to be elucidated.
The rapid restoration of estrous cyclicity in the PCOS EA group is
Figure 2. Western blot analysis of AR, p21, and c-Fos protein
expression in the hypothalamus. Regulation of AR, p21, and c-Fos
protein expression in the hypothalamus in the control (n=7), PCOS
(n=6), and PCOS EA (n=6) groups. Top: total protein (50 mg) was
isolated and used for western blot analysis. The blot is representative of
each run with independent samples. Bottom: densitometric analysis of
the levels of AR, p21, and c-Fos protein expression. Equal sample
loading was confirmed by Coomassie blue staining. Relative levels of
AR, p21, and c-Fos proteins were expressed as a ratio of densitometric
value to whole proteins in Coomassie blue–stained gels. Values are
mean6SEM of two independent experiments (n=3 pools/group).
***p,0.001, **p,0.01 vs. control; ##p,0.05 vs. PCOS.
doi:10.1371/journal.pone.0006638.g002
Neuroendocrine Effects of EA
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ovarian morphology we previously observed in rats with DHT-
induced PCOS [13]. However, the estrous cycle changes weremore
prominent in the present study, perhaps because the treatments
were more frequent (five versus three times per week).
Low-frequency EA did not affect hypothalamic CRH concen-
trations, which is in line with our finding that EA does not affect
corticosterone concentrations [11]. In the EV-induced PCO
model, however, the CRH concentration was increased in the
median eminence, indicating increased activity in the hypothal-
amus-pituitary-adrenal axis, but was restored to normal by
repeated low-frequency EA [16]. Furthermore, in the present
study, there was no difference in the weight of the adrenal glands
between the PCOS and PCOS EA groups (PCOS, 45.062.1 mg;
PCOS EA, 48.661.6 mg). Notably, these results support the
findings that handling and treatment are not stressful for the rats.
These findings do not completely exclude the involvement of
estrogen receptor (ER) b activation in the MPO, since DHT can
be metabolized into 5a-androstane-3b and 17b-diol (3b-diol),
which can act via the ERb receptor [43]. In the hypothalamus, the
VMH expresses mainly ERa [44], whereas the PVN contains only
ERb [45]. In DHT-treated rats in the present study, AR
expression was mainly increased in the MPO and to a lesser
extent in the VMH, but was unaltered in the PVN.
In conclusion, this study demonstrates that rats with DHT-
induced PCOS have hypothalamic GnRH abnormalities that are
most likely mediated by AR activation. Low-frequency EA 5 days
per week improved estrous cyclicity and reduced GnRH and AR
protein expression. A possible mechanism for these effects is direct
regulation of AR on GnRH-expressing neurons in the MPO.
These results may partly explain the beneficial neuroendocrine
effects of low-frequency EA in women with PCOS.
Materials and Methods
Rats and ethics statement
Four Wistar dams, each with eight to nine female pups, were
purchased from Charles River (Sulzfeld, Germany), raised with a
Figure 3. AR-ir cells in the medial preoptic area (MPO) and ventromedial hypothalamus (VMH). A) Light micrographs of AR-ir cells,
detected with polyclonal antibody as described in Materials and Methods. Scale bar, 100 mm. B) Quantification of AR-ir cells in the different regions in
the control (n=5), PCOS (n=6), and PCOS EA (n=6) groups. Values are mean6SEM. **p,0.01 vs. control; ##p,0.01 vs. PCOS, #p,0.05 vs. PCOS.
doi:10.1371/journal.pone.0006638.g003
Neuroendocrine Effects of EA
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cage under controlled conditions (21–22uC, 55–65% humidity, 12-
h light, 12-h dark cycle). Rats were fed commercial chow (Harlan
Teklad Global Diet, 16% protein rodent diet nr 2016, Harlan
Winkelmann Gmbh, Harlan, Germany) and tap water ad libitum.
Animals were cared for in accordance with the principles of the
Guide to the Care and Use of Experimental Animals (www.sjv.se).
The study was approved by the Animal Ethics Committee of the
University of Gothenburg.
Study procedure
At 21 days of age, rats were randomly divided into three
experimental groups (control, PCOS, and PCOS EA; n=12 per
group) and implanted subcutaneously with 90-day continuous-
release pellets (Innovative Research of America, Sarasota, FL)
containing 7.5 mg of DHT (daily dose, 83 mg) or 7.5 mg of
vehicle. In our previous study, this dose of DHT resulted in PCOS
characteristics, including metabolic disturbances at adult age [46].
A microchip (AVID, Norco, CA) with an identification number
Figure 4. GnRH-ir cells in the rostral MS, MPO, and HDB of the hypothalamus. A) Light micrographs of GnRH-ir cells, detected with
polyclonal antibody as described in Materials and Methods. Scale bar, 100 mm. B) Quantification of GnRH-ir cells in the different regions in the control
(n=5), PCOS (n=6), and PCOS EA (n=6) groups. Values are mean6SEM. *p,0.05 vs. control; #p,0.05 vs. PCOS. C) Immunoprecipitation and
western blot (WB) of GnRH protein in the hypothalamus.
doi:10.1371/journal.pone.0006638.g004
Neuroendocrine Effects of EA
PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6638Figure 5. GnRH-R-ir cells in the rostral MS, and nucleus of the HDB of the hypothalamus and pituitary (Pit). A) Light micrographs of the
GnRH-R-ir cells, detected with polyclonal antibodies as described in Materials and Methods. Scale bar, 100 mm. B) Quantification of GnRH-R cells in
the control (n=5), PCOS (n=6), and PCOS EA (n=6) groups. Values are mean6SEM. *p,0.05 vs. control; #p,0.05 vs. PCOS. C) Western blot of
GnRH-R protein in the hypothalamus. Total protein (50 mg) was isolated and used for western blot analysis. The blot is representative of two
essentially similar experiments, each run with independent samples. Densitometric analysis of GnRH-R protein expression in two independent
experiments. Equal sample loading was confirmed by Coomassie blue staining. Relative levels of GnRH-R proteins were expressed as a ratio of
densitometric value to whole proteins in Coomassie blue–stained gels. Data are expressed as ADU; values are the mean6SEM of two independent
experiments (n=3 pools/group). *p,0.05 vs. control.
doi:10.1371/journal.pone.0006638.g005
Neuroendocrine Effects of EA
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were identical to the DHT pellets but without the bioactive
molecule. All rats were weighed weekly from 21 days of age.
Treatments started at 70 days of age, after 7 weeks of DHT
exposure. The study was concluded after 12 weeks of DHT
exposure, including 4–5 weeks of EA.
EA treatment
Low-frequency EA was given to conscious rats daily from
Monday to Friday for 4–5 weeks (20–25 treatments in total). The
treatment duration was 15 min in week 1, 20 min in weeks 2 and
3, and 25 min thereafter. Acupuncture needles were inserted in
the rectus abdominis (stomach) [29] and in the triceps surae
muscles (spleen) [6] bilaterally, in somatic segments that
correspond to the innervation of the ovaries (i.e., from spinal
levels T10 to L2 and at the sacral level). The needles (HEGU
Svenska, Landsbro, Sweden) were inserted to a depth of 0.5–
0.8 cm and attached to an electric stimulator (CEFAR ACU II;
Cefar-Compex Scandinavia, Malmo, Sweden). The points were
electrically stimulated with a low frequency of 2 Hz with 0.1-sec,
80-Hz burst pulses [12–16]. The intensity was adjusted to produce
local muscle contractions and varied from 0.8–1.4 mA during the
stimulation period. Because of receptor adaptation, the amplitude
varied during each treatment. Most rats required higher amplitude
at the end of the stimulation period.
Before handling or needle insertion, all rats were lightly
anesthetized with isoflurane (2% in a 1:1 mixture of oxygen and
air; Isoba vet; Schering-Plough, Stockholm, Sweden) for 2–3 min.
One investigator inserted all needles. During EA treatment, the
rats were placed in a fabric harness and suspended above the desk.
Figure 6. CRH-ir cells in the PVN and MPO in control, PCOS and PCOS EA rats. A) Light micrographs of CRH-ir cells, detected with
polyclonal antibodies as described in Materials and Methods. Scale bar, 100 mm. B) Quantification of CRH-ir cells in the different regions in the control
(n=5), PCOS (n=6), and PCOS EA (n=6) groups. Values are mean6SEM. C) Protein samples were isolated from the hypothalamus of control, PCOS,
and PCOS EA rats. Total protein (50 mg) was isolated and used for western blot analysis. The blot is representative of two essentially similar
experiments, each run with independent samples. Densitometric analysis of CRH protein expression in two independent experiments. Equal sample
loading was confirmed by Coomassie blue staining. Relative levels of CRH proteins were expressed as a ratio of densitometric value to whole proteins
in Coomassie blue–stained gels. Data are expressed as ADU. Values are mean6SEM of two independent experiments (n=3 pools/group).
doi:10.1371/journal.pone.0006638.g006
Neuroendocrine Effects of EA
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performed 24 h before examinations and blood sampling. Rats
in the control and PCOS groups were anesthetized, suspended in a
harness, and handled in the same way as rats in the PCOS EA
group but without needle insertion or electrical stimulation. All
rats were conscious during handling and treatment.
Vaginal smears
The stage of cyclicity was determined by microscopic analysis of
the predominant cell type in vaginal smears obtained daily from
the onset of EA treatment at 70 days of age to the end of the
experiment.
Immunohistochemistry
For 3, 39-diaminobenzidine staining, five control rats and six
rats each in the PCOS and PCOS EA groups were deeply
anesthetized with thiobutabarbital sodium (130 mg/kg i.p.;
Inactin, Sigma, St. Louis, MO) and perfused via the left cardiac
ventricle with 4uC cold 0.9% sodium chloride (200 ml) and
Histofix (Histolab, Gothenburg, Sweden) (100 ml) for rapid
Figure 7. Co-localization of AR, GnRH, and CRH in MPO neurons, determined by dual-fluorescence immunohistochemistry and
confocal laser-scanning microscopy. A) Main distribution of AR, GnRH, and CRH in control female rat brain (3v=third ventricle). Adapted from
reference [47]. B–D) Co-localization of AR, GnRH, CRH, and NeuN immunoreactivity in MPO neurons. E) Co-localization of rabbit polyclonal AR
antibody and mouse monoclonal AR antibody in hypothalamic MPO. F and G) Co-localization of mouse monoclonal AR antibody with GnRH or CRH
immunoreactivity in hypothalamic MPO neurons. In panels B–G, arrows indicate co-localization. Scale bars, 100 mm.
doi:10.1371/journal.pone.0006638.g007
Neuroendocrine Effects of EA
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containing 20% sucrose for 48 h at 4uC and subsequently in
0.1 M PBS containing 30% sucrose for at least 24 h at 4uC.
Serially frozen frontal sections (20 mm) were cut and stored in
tissue culture wells containing 30% sucrose and 30% ethylene
glycol in 0.1 M PBS, pH 7.4, at 220uC. The brain sections were
taken from the hypothalamus (20.40 and 23.60 mm from the
bregma) [47], washed in 0.01 M PBS (Sigma) for GnRH and
CRH experiments or in Tris-buffered saline (50 mM Tris, 0.9%
NaCl, pH 7.5) for AR experiments; the endogenous peroxidase
and nonspecific binding were removed by incubation with 3%
H2O2 for 30 min and 0.5% Triton X-100 10 min at room
temperature. The sections were then incubated with 10% normal
horse serum for 1 h at 37uC and with primary antibody (Table 1)
for 1 h at 37uC and then overnight at 4uC. Sections were stained
with the avidin–biotinylated peroxidase complex detection system
(ABC kit, Vector Laboratories, Burlingame, CA) according to the
manufacturer’s instructions and treated for 1 min with 3, 39-
diaminobenzidine. Sections were examined with an Olympus
DP50 microscope (Japan) under bright-field optics and photo-
graphed with Image-pro plus software (version 5.0, Media
Cybernetics, Bethesda, MD) to count cells. Five sections were
chosen in the same area to calculate the mean cell population. The
positive cells were counted by up-down focusing.
For dual-fluorescence immunohistochemistry, hypothalamic
sections were blocked in goat normal serum for 2 h at 37uC.
Slides were incubated with two different primary antibodies in
16TBS supplemented with 0.05% Triton X-100 (TBST) for 2 h
at 37uC and overnight at 4uC. After five 10-min washes in TBST,
sections were incubated with the first secondary antibody at 37uC
for 1 h, washed five times with TBST for 10 min each, and
incubated with the second secondary antibody at 37uC for 1 h.
Sections were washed in TBST as above and mounted with
fluorescent Vectashield with 49, 6-diamidino-2-phenylindole
(DAPI). All fluorescence images were acquired with an Axiovert
200/LSM 510 META laser-scanning confocal microscopy system
(Zeiss, Jena, Germany) fitted with a Plan-Apochromat 63x/1.40
Oil DIC objective. Background settings were determined by
examination of negative control specimens.
Images of positive staining were adjusted to make optimal use of
the dynamic range of detection. All final immunohistochemistry
was carried out in parallel under identical conditions. To control for
nonspecific staining, adjacent sections were stained as above, except
the primary antibody was replaced with TBST, normal rabbit IgG,
or mouse IgG. TBST was used to control for nonspecific staining of
the secondary antibody and to obtain the background level. Rabbit
or mouse IgG was used to ensure that there was no cross-reactivity
between the two staining sequences. Rat testis served as a positive
control for AR. Rat placenta served as a positive control for GnRH
and CRH. The immunohistochemical findings are representative
of those observed in random sections from multiple animals. The
staining was evaluated by two blinded observers.
Table 1. Antibodies: species, clone/catalog number, method, dilution, and source.
Antibody Species Clone/Cat. Method Dilution
* Source
Primary
AR Rabbit sc-816 IHC 1:200 Santa Cruz Biotechnology,
WB 1:250 Santa Cruz, CA
Mouse AR441 IF 1:50 Dako, Glostrup, Denmark
GnRH Rabbit G8294 IHC 1:5000 Sigma Chemical, St. Louis,
IP 1:1000 MO
CRH Chicken XW-7122 IHC 1:200 ProSciPoway, CA
Rabbit C5348 WB 1:100 Sigma Chemical
IF 1:200
GnRH-R Rabbit sc-13944 IHC 1:100 Santa Cruz Biotechnology
WB 1:200
p21 Mouse sc-6246 WB 1:250 Santa Cruz Biotechnology
c-Fos Rabbit WB 1:200 Calbiochem, Gibbstown, NJ
b-actin Mouse AC-15 WB 1:1000 Sigma Chemical
Secondary
Anti-chicken IgY (IgG) Rabbit A9046 IHC 1:200 Sigma Chemical
Alexa Fluor-568 anti-rabbit IgG Donkey A10042 IF 1:250 Invitrogen, Carlsbad, CA
Alexa Fluor-488 NeuN MAB377X IF 1:100 Millipore, Billerica, MA
Texas Red anti-mouse IgG Horse TI-2000 IF 1:200 Vector Laboratories,
Burlingame, CA
Biotinylated anti-rabbit IgG Goat BA-1000 IF 1:500 Vector Laboratories
Fluorescein streptavidin SA-5001 IF 1:200 Vector Laboratories
alkaline phosphatase-conjugated anti-rabbit IgG Goat T2191 WB 1:40000 Tropix, Bedford, MA
Alkaline phosphatase–conjugated anti-mouse IgG Goat A-1682 WB 1:80000 Sigma Chemical
NeuN: Neuronal nuclei; IHC: immunohistochemistry; IF: immunofluorescence; WB: western blot analysis; IgG, immunoglobulin G.
*Optimal working dilutions determined in preliminary experiments.
doi:10.1371/journal.pone.0006638.t001
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The remaining rats (seven controls and six each from the PCOS
and PCOS EA groups) were used to investigate AR, GnRH, and
CRH protein expression by western blot. The target regions,
including the mediobasal hypothalamus and suprachiasmatic-
preoptic area were dissected (limited anteriorly by the optic
chiasma, laterally by the hypothalamic fissures, posteriorly by the
mammilary bodies, and in depth by the subthalamic sulcus).
Tissue protein was prepared as described [48]. Protein concen-
trations were determined with the BCA protein assay (Pierce,
Rockford, IL), using bovine serum albumin as the standard.
Expression of AR, p21, and c-FOS was detected by western blot
analysis with a standard procedure [49]. Protein aliquots were
pretreated with 46sodium dodecyl sulfate (SDS) (1650 mM Tris-
HCl, 2% SDS, 10% glycerol, 10% b-mercaptoethanol, and 0.001%
bromophenol blue) before loading and separated on 4–12% SDS-
polyacrylamide gels (Novex, Invitrogen, Carlsbad, CA) with a Bis-
Tris-MOPS buffer system under reducing conditions. The separat-
ed samples were electrophoretically transferred to polyvinyldifluor-
ide membranes (Amersham International, Buckinghamshire, UK)
and incubated with primary antibody (Table 1) in blocking buffer
overnight at 4uC. The next day, the membranes were incubated
with alkaline phosphatase–conjugated goat anti-rabbit or goat anti-
mouse antibody and detected with CDP-Star substrate for alkaline
phosphatase (Tropix, Bedford, MA). Immunoblotted signals were
exposed and developed with ECL film (Amersham International)
and directly from membranes by densitometry with ImageQuant
software (version 5.0, Molecular Dynamics, Sunnyvale, CA). Signal
intensities of the AR, p21, and c-FOS proteins were normalized to
those of gels stained with Coomassie blue as ratios to produce
arbitrary densitometric units (ADU) of relative abundance. Care
was taken to ensure that the ADU of all bands considered was in the
range of linearity previously assessed.
Immunoprecipitation
For immunoprecipitation experiments [50], tissues were ex-
tracted with ice-cold lysis buffer (25 mM Tris–HCl, pH 8.0,
150 mM NaCl, 0.5% Nonidet P-40, 1% SDS, 200 M sodium
deoxycholate, 1 mM dithiothreitol, 5 mM EDTA, 0.5 mM
phenylmethyl sulfonyl fluoride, and a cocktail of protease
inhibitors (Roche Diagnostics, Mannheim, Germany). Specific
antibodies against GnRH were added to 500 mg of protein extracts
and incubated for 4 h at room temperature. Immune complexes
were obtained by adding 50 ml of Pansorbin cells (Calbiochem,
San Diego, CA). The resulting immobilized immune complexes
were washed in RIPA buffer (50 mM Tris–HCl, pH 7.8, 150 mM
NaCl, 15 mM MgCl2, 0.5% Nonidet P-40, 0.3% Triton X-100,
0.5% sodium deoxycholate, 5 mM EDTA, 1 mM dithiothreitol,
and a cocktail of protease inhibitors). The bound protein was
eluted by boiling in 30 ml of SDS sample reducing/loading buffer
(Novex) for 5 min. Immunoprecipitated complexes were loaded in
the 4–12% SDS-polyacrylamide gels (Novex).
Data analysis and statistics
Data are expressed as mean6SEM of the number of
independent experiments indicated in the figure legends. Multiple
comparisons were performed with one-way ANOVA followed by
correction of P values with Dunnett’s posthoc test (SPSS, version
16.0; Chicago, IL). P,0.05 was set as the limit of statistical
significance.
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